Therapies using anti-angiogenic peptide mimetics of thrombospondin-1

Bibliography

• Good DJ, Polverini PJ, Rastinejad F, A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 1990;87:6624-8
   PubMed Web of Science ®Google Scholar
• Kazerounian S, Yee KO, Lawler J. Thrombospondins in cancer. Cell Mol Life Sci 2008;65:700-12
   PubMed Web of Science ®Google Scholar
• Carlson CB, Lawler J, Mosher DF. Structures of thrombospondins. Cell Mol Life Sci 2008;283:672-86
   Web of Science ®Google Scholar
• Silverstein RL, Li W, Park YM, Rahaman SO. Mechanisms of cell signaling by the scavenger receptor CD36: implications in atherosclerosis and thrombosis. Trans Am Clin Climatol Assoc 2010;121:206-20
   PubMedGoogle Scholar
• Simantov R, Silverstein RL. CD36: a critical anti-angiogenic receptor. Front Biosci 2003;8:s874-82
   Web of Science ®Google Scholar
• Dawson DW, Pearce SF, Zhong R, CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 1997;138:707-17
   PubMed Web of Science ®Google Scholar
• Jimenez B, Volpert OV, Crawford SE, Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 2000;6:41-8
   PubMed Web of Science ®Google Scholar
• Ridnour LA, Thomas DD, Donzelli S, The biphasic nature of nitric oxide responses in tumor biology. Antioxid Redox Signal 2006;8:1329-37
   PubMed Web of Science ®Google Scholar
• Hou J, Putkey JA, Hecht JT. Delta469 mutation in the type 3 repeat calcium binding domain of cartilage oligomeric matrix protein (COMP) disrupts calcium binding. Cell Calcium 2000;27:309-14
   PubMed Web of Science ®Google Scholar
• Wilson KE, Li Z, Kara M, beta1 integrin- and proteoglycan-mediated stimulation of T lymphoma cell adhesion and mitogen-activated protein kinase signaling by thrombospondin-1 and thrombospondin-1 peptides. J Immunol 1999;163:3621-8
   PubMed Web of Science ®Google Scholar
• Isenberg JS, Pappan LK, Romeo MJ, Blockade of thrombospondin-1-CD47 interactions prevents necrosis of full thickness skin grafts. Ann Surg 2008;247:180-90
   PubMed Web of Science ®Google Scholar
• Bornstein P. Thrombospondins function as regulators of angiogenesis. J Cell Commun Signal 2009;3:189-200
   PubMed Web of Science ®Google Scholar
• Murphy-Ullrich JE, Poczatek M. Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev 2000;11:59-69
   PubMed Web of Science ®Google Scholar
• Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med 2002;6:1-12
   PubMed Web of Science ®Google Scholar
• Greenaway J, Lawler J, Moorehead R, Thrombospondin-1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor-related protein-1 (LRP-1). J Cell Physiol 2007;210:807-18
   PubMed Web of Science ®Google Scholar
• Adams JC, Lawler J. The thrombospondins. Int J Biochem Cell Biol 2004;36:961-8
   PubMed Web of Science ®Google Scholar
• Zhang X, Lawler J. Thrombospondin-based antiangiogenic therapy. Microvasc Res 2007;74:90-9
   PubMed Web of Science ®Google Scholar
• Hoekstra R, de Vos FY, Eskens FA, Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: a safe combination. Eur J Cancer 2006;42:467-72
   PubMed Web of Science ®Google Scholar
• Wang XQ, Lindberg FP, Frazier WA. Integrin-associated protein stimulates alpha2beta1-dependent chemotaxis via Gi-mediated inhibition of adenylate cyclase and extracellular-regulated kinases. J Cell Biol 1999;147:389-400
   PubMed Web of Science ®Google Scholar
• Carlson CB, Lawler J, Mosher DF. Thrombospondins: from structure to therapeutics: structures of thrombospondins. Cell Mol Life Sci 2008;65:672-86
   PubMed Web of Science ®Google Scholar
• Margosio B, Rusnati M, Bonezzi K, Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domain. Int J Biochem Cell Biol 2008;40:700-9
   PubMed Web of Science ®Google Scholar
• Tolsma SS, Volpert OV, Good DJ, Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol 1993;122:497-511
   PubMed Web of Science ®Google Scholar
• Miyata Y, Koga S, Takehara K, Expression of thrombospondin-derived 4N1K peptide-containing proteins in renal cell carcinoma tissues is associated with a decrease in tumor growth and angiogenesis. Clin Cancer Res 2003;9:1734-40
   PubMed Web of Science ®Google Scholar
• Kanda S, Shono T, Tomasini-Johansson B, Role of thrombospondin-1-derived peptide, 4N1K, in FGF-2-induced angiogenesis. Exp Cell Res 1999;252:262-72
   PubMed Web of Science ®Google Scholar
• Isenberg JS, Calzada MJ, Zhou L, Endogenous thrombospondin-1 is not necessary for proliferation but is permissive for vascular smooth muscle cell responses to platelet-derived growth factor. Matrix Biol 2005;24:110-23
   PubMed Web of Science ®Google Scholar
• Gupta K, Gupta P, Wild R, Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: Effect on human microvascular endothelial cell proliferation and angiogenesis. Angiogenesis 1999;3:147-58
   PubMedGoogle Scholar
• Margosio B, Marchetti D, Vergani V, Thrombospondin 1 as a scavenger for matrix-associated fibroblast growth factor 2. Blood 2003;102:4399-406
   PubMed Web of Science ®Google Scholar
• Johansson U, Higginbottom K, Londei M. CD47 ligation induces a rapid caspase-independent apoptosis-like cell death in human monocytes and dendritic cells. Scand J Immunol 2004;59:40-9
   Google Scholar
• Ren B, Yee KO, Lawler J, Khosravi-Far R. Regulation of tumor angiogenesis by thrombospondin-1. Biochim Biophys Acta 2006;1765:178-88
   PubMed Web of Science ®Google Scholar
• Armstrong LC, Bjorkblom B, Hankenson KD, Thrombospondin 2 inhibits microvascular endothelial cell proliferation by a caspase-independent mechanism. Mol Biol Cell 2002;13:1893-905
   PubMed Web of Science ®Google Scholar
• Guo N, Krutzsch HC, Inman JK, Roberts DD. Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res 1997;57:1735-42
   PubMed Web of Science ®Google Scholar
• Iruela-Arispe ML, Lombardo M, Krutzsch HC, Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. Circulation 1999;100:1423-31
   PubMed Web of Science ®Google Scholar
• Dawson DW, Volpert OV, Pearce SF, Three distinct d-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat. Mol Pharmacol 1999;55:332-8
   PubMed Web of Science ®Google Scholar
• Elzie CA, Murphy-Ullrich JE. The N-terminus of thrombospondin: the domain stands apart. Int J Biochem Cell Biol 2004;36:1090-101
   PubMed Web of Science ®Google Scholar
• Gonias SL, Wu L, Salicioni AM. Low density lipoprotein receptor-related protein: Regulation of the plasma membrane proteome. Thromb Haemost 2004;91:1056-64
   PubMed Web of Science ®Google Scholar
• Silverstein RL, Febbraio M. CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci Signal 2009;2:re3
   PubMed Web of Science ®Google Scholar
• Kuriki K, Hamajima N, Chiba H, Increased risk of colorectal cancer due to interactions between meat consumption and the CD36 gene A52C polymorphism among Japanese. Nutr Cancer 2005;51:170-7
   PubMed Web of Science ®Google Scholar
• Mirochnik Y, Kwiatek A, Volpert OV. Thrombospondin and apoptosis: Molecular mechanisms and use for design of complementation treatments. Curr Drug Targets 2008;9:851-62
   PubMed Web of Science ®Google Scholar
• Simantov R, Febbraio M, Silverstein RL. The antiangiogenic effect of thrombospondin-2 is mediated by CD36 and modulated by histidine-rich glycoprotein. Matrix Biol 2005;24:27-34
   PubMed Web of Science ®Google Scholar
• Asch AS, Liu I, Briccetti FM, Analysis of CD36 binding domains: Ligand specificity controlled by dephosphorylation of an ectodomain. Science 1993;262:1436-40
   PubMed Web of Science ®Google Scholar
• Klenotic PA, Huang P, Palomo J, Histidine-rich glycoprotein modulates the anti-angiogenic effects of vasculostatin. Am J Pathol 2010;176:2039-50
   PubMed Web of Science ®Google Scholar
• Daviet L, Malvoisin E, Wild TF, McGregor JL. Thrombospondin induces dimerization of membrane-bound, but not soluble CD36. Thromb Haemost 1997;78:897-901
   PubMed Web of Science ®Google Scholar
• Volpert OV, Zaichuk T, Zhou W, Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med 2002;8:349-57
   PubMed Web of Science ®Google Scholar
• Aurora AB, Biyashev D, Mirochnik Y, NF-kappaB balances vascular regression and angiogenesis via chromatin remodeling and NFAT displacement. Blood 2010;116:475-84
   PubMed Web of Science ®Google Scholar
• Zaichuk TA, Shroff EH, Emmanuel R, Nuclear factor of activated T cells balances angiogenesis activation and inhibition. J Exp Med 2004;199:1513-22
   PubMed Web of Science ®Google Scholar
• Ren B, Song K, Parangi S, A double hit to kill tumor and endothelial cells by TRAIL and antiangiogenic 3TSR. Cancer Res 2009;69:3856-65
   PubMed Web of Science ®Google Scholar
• Rege TA, Stewart J Jr, Dranka B, Thrombospondin-1-induced apoptosis of brain microvascular endothelial cells can be mediated by TNF-R1. J Cell Physiol 2009;218:94-103
   PubMed Web of Science ®Google Scholar
• Isenberg JS, Annis DS, Pendrak ML, Differential interactions of thrombospondin-1, -2, and -4 with CD47 and effects on cGMP signaling and ischemic injury responses. J Biol Chem 2009;284(2):1116-25
   PubMed Web of Science ®Google Scholar
• McDonald JF, Dimitry JM, Frazier WA. An amyloid-like c-terminal domain of thrombospondin-1 displays CD47 agonist activity requiring both VVM motifs. Biochemistry 2003;284:10001-11
   Web of Science ®Google Scholar
• Kvansakul M, Adams JC, Hohenester E. Structure of a thrombospondin C-terminal fragment reveals a novel calcium core in the type 3 repeats. EMBO J 2004;23:1223-33
   PubMed Web of Science ®Google Scholar
• Floquet N, Dedieu S, Martiny L, Human thrombospondin's (TSP-1) C-terminal domain opens to interact with the CD-47 receptor: a molecular modeling study. Arch Biochem Biophys 2008;478:103-9
   PubMed Web of Science ®Google Scholar
• Gao AG, Lindberg FP, Finn MB, Integrin-associated protein is a receptor for the C-terminal domain of thrombospondin. J Biol Chem 1996;271:21-4
   PubMed Web of Science ®Google Scholar
• Gao AG, Frazier WA. Identification of a receptor candidate for the carboxyl-terminal cell binding domain of thrombospondins. J Biol Chem 1994;269:29650-7
   PubMed Web of Science ®Google Scholar
• Miller TW, Isenberg JS, Roberts DD. Thrombospondin-1 is an inhibitor of pharmacological activation of soluble guanylate cyclase. Br J Pharmacol 2010;159:1542-7
   PubMed Web of Science ®Google Scholar
• Isenberg JS, Frazier WA, Krishna MC, Enhancing cardiovascular dynamics by inhibition of thrombospondin-1/CD47 signaling. Curr Drug Targets 2008;9:833-41
   PubMed Web of Science ®Google Scholar
• Maxhimer JB, Soto-Pantoja DR, Ridnour LA, Radioprotection in normal tissue and delayed tumor growth by blockade of CD47 signaling. Sci Transl Med 2009;1:3ra7
   PubMed Web of Science ®Google Scholar
• Ridnour LA, Thomas DD, Switzer C, Molecular mechanisms for discrete nitric oxide levels in cancer. Nitric Oxide 2008;19:73-6
   PubMed Web of Science ®Google Scholar
• Isenberg JS, Frazier WA, Roberts DD. Thrombospondin-1: a physiological regulator of nitric oxide signaling. Cell Mol Life Sci 2008;65:728-42
   PubMed Web of Science ®Google Scholar
• Kaur S, Martin-Manso G, Pendrak ML, Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47. J Biol Chem 2010;285:38923-32
   PubMed Web of Science ®Google Scholar
• Frazier EP, Isenberg JS, Shiva S, Age-dependent regulation of skeletal muscle mitochondria by the thrombospondin-1 receptor CD47. Matrix Biol 2011;30:154-61
   PubMed Web of Science ®Google Scholar
• Bauer EM, Qin Y, Miller TW, Thrombospondin-1 supports blood pressure by limiting eNOS activation and endothelial-dependent vasorelaxation. Cardiovasc Res 2010;88:471-81
   PubMed Web of Science ®Google Scholar
• Isenberg JS, Hyodo F, Pappan LK, Blocking thrombospondin-1/CD47 signaling alleviates deleterious effects of aging on tissue responses to ischemia. Arterioscler Thromb Vasc Biol 2007;27:2582-8
   PubMed Web of Science ®Google Scholar
• Burnworth B, Arendt S, Muffler S, The multi-step process of human skin carcinogenesis: a role for p53, cyclin D1, hTERT, p16, and TSP-1. Eur J Cell Biol 2007;86:763-80
   PubMed Web of Science ®Google Scholar
• Bleuel K, Popp S, Fusenig NE, Tumor suppression in human skin carcinoma cells by chromosome 15 transfer or thrombospondin-1 overexpression through halted tumor vascularization. Proc Natl Acad Sci USA 1999;96:2065-70
   PubMed Web of Science ®Google Scholar
• Fusenig NE, Boukamp P. Multiple stages and genetic alterations in immortalization, malignant transformation, and tumor progression of human skin keratinocytes. Mol Carcinog 1998;23:144-58
   PubMed Web of Science ®Google Scholar
• Liu BL, Cheng JX, Zhang W, Quantitative detection of multiple gene promoter hypermethylation in tumor tissue, serum, and cerebrospinal fluid predicts prognosis of malignant gliomas. Neuro Oncol 2010;12:540-8
   PubMed Web of Science ®Google Scholar
• Guo W, Dong Z, He M, Aberrant methylation of thrombospondin-1 and its association with reduced expression in gastric cardia adenocarcinoma. J Biomed Biotechnol 2010;2010:721485
   PubMedGoogle Scholar
• Oue N, Matsumura S, Nakayama H, Reduced expression of the TSP1 gene and its association with promoter hypermethylation in gastric carcinoma. Oncology 2003;64:423-9
   PubMed Web of Science ®Google Scholar
• Kang GH, Shim YH, Jung HY, CpG island methylation in premalignant stages of gastric carcinoma. Cancer Res 2001;61:2847-51
   PubMed Web of Science ®Google Scholar
• Yang Q, Tian Y, Ostler KR, Epigenetic alterations differ in phenotypically distinct human neuroblastoma cell lines. BMC Cancer 2010;10:286
   PubMed Web of Science ®Google Scholar
• Hu CJ, Chen SD, Yang DI, Promoter region methylation and reduced expression of thrombospondin-1 after oxygen-glucose deprivation in murine cerebral endothelial cells. J Cereb Blood Flow Metab 2006;26:151-1526
   Web of Science ®Google Scholar
• Michaud-Levesque J, Richard S. Thrombospondin-1 is a transcriptional repression target of PRMT6. J Biol Chem 2009;284:21338-46
   PubMed Web of Science ®Google Scholar
• Phelan MW, Forman LW, Perrine SP, Faller DV. Hypoxia increases thrombospondin-1 transcript and protein in cultured endothelial cells. J Lab Clin Med 1998;132:519-29
   PubMed Web of Science ®Google Scholar
• Chen JK, Zhan YJ, Yang CS, Tzeng SF. Oxidative stress-induced attenuation of thrombospondin-1 expression in primary rat astrocytes. J Cell Biochem 2011;112:59-70
   PubMed Web of Science ®Google Scholar
• Raman P, Harry C, Weber M, A novel transcriptional mechanism of cell type-specific regulation of vascular gene expression by glucose. Arterioscler Thromb Vasc Biol 2011;31:634-42
   Google Scholar
• Garcia-Diaz DF, Arellano AV, Milagro FI, Glucose and insulin modify thrombospondin 1 expression and secretion in primary adipocytes from diet-induced obese rats. J Physiol Biochem 2011;67:453-61
   PubMed Web of Science ®Google Scholar
• Zhou W, Dasgupta C, Negash S, Raj JU. Modulation of pulmonary vascular smooth muscle cell phenotype in hypoxia: role of cGMP-dependent protein kinase. Am J Physiol Lung Cell Mol Physiol 2007;292:L1459-66
   Web of Science ®Google Scholar
• Sheibani N, Sorenson CM, Cornelius LA Frazier WA. Thrombospondin-1, a natural inhibitor of angiogenesis, is present in vitreous and aqueous humor and is modulated by hyperglycemia. Biochem Biophys Res Commun 2000;267:257-61
   PubMed Web of Science ®Google Scholar
• Bongrazio M, Da Silva-Azevedo L, Bergmann EC, Shear stress modulates the expression of thrombospondin-1 and CD36 in endothelial cells in vitro and during shear stress-induced angiogenesis in vivo. Int J Immunopathol Pharmacol 2006;19:35-48
   PubMed Web of Science ®Google Scholar
• Freyberg MA, Kaiser D, Graf R, Proatherogenic flow conditions initiate endothelial apoptosis via thrombospondin-1 and the integrin-associated protein. Biochem Biophys Res Commun 2001;286:141-9
   PubMed Web of Science ®Google Scholar
• Freyberg MA, Kaiser D, Graf R, Integrin-associated protein and thrombospondin-1 as endothelial mechanosensitive death mediators. Biochem Biophys Res Commun 2000;271:584-8
   Google Scholar
• Lu P, Li L, Kuno K, Protective roles of the fractalkine/CX3CL1-CX3CR1 interactions in alkali-induced corneal neovascularization through enhanced antiangiogenic factor expression. J Immunol 2008;180:4283-91
   PubMed Web of Science ®Google Scholar
• Yang G, Rosen DG, Liu G, CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clin Cancer Res 2010;16:3875-86
   PubMed Web of Science ®Google Scholar
• Wen XF, Yang G, Mao W, HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: Implications for HER2-targeted antibody therapy. Oncogene 2006;25:6986-96
   PubMed Web of Science ®Google Scholar
• Culp WD, Tsagozis P, Burgio M, Interference of macrophage migration inhibitory factor expression in a mouse melanoma inhibits tumor establishment by up-regulating thrombospondin-1. Mol Cancer Res 2007;5:1225-31
   PubMed Web of Science ®Google Scholar
• Morandi V, Cherradi SE, Lambert S, Proinflammatory cytokines (interleukin-1beta and tumor necrosis factor-alpha) down regulate synthesis and secretion of thrombospondin by human endothelial cells. J Cell Physiol 1994;160:367-77
   PubMed Web of Science ®Google Scholar
• He J, Eastlack JP, Bazan HE. The induction of an angiogenic response in corneal myofibroblasts by platelet-activating factor (PAF). Curr Eye Res 2010;35:1063-71
   PubMed Web of Science ®Google Scholar
• Kuhn I, Bartholdi MF, Salamon H, Identification of AKT-regulated genes in inducible MERAkt cells. Physiol Genomics 2001;7:105-14
   PubMed Web of Science ®Google Scholar
• Ghoneim C, Soula-Rothhut M, Blanchevoye C, Activating transcription factor-1-mediated hepatocyte growth factor-induced down-regulation of thrombospondin-1 expression leads to thyroid cancer cell invasion. J Biol Chem 2007;282:15490-7
   PubMed Web of Science ®Google Scholar
• Zhang YW, Su Y, Volpert OV, Vande Woude GF. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci USA 2003;100:12718-23
   PubMed Web of Science ®Google Scholar
• Goel HL, Moro L, Murphy-Ullrich JE, beta1 integrin cytoplasmic variants differentially regulate expression of the antiangiogenic extracellular matrix protein thrombospondin 1. Cancer Res 2009;69:5374-82
   PubMed Web of Science ®Google Scholar
• El Btaouri H, Morjani H, Greffe Y, Role of JNK/ATF-2 pathway in inhibition of thrombospondin-1 (TSP-1) expression and apoptosis mediated by doxorubicin and camptothecin in FTC-133 cells. Biochim Biophys Acta 2011;1813:695-703
   PubMed Web of Science ®Google Scholar
• Ji W, Zhang W, Xiao W. E2F-1 directly regulates thrombospondin 1 expression. PLoS One 2010;15:e13442
   Web of Science ®Google Scholar
• Matsushita S, Ikeda R, Nishizawa Y, The role of thymidine phosphorylase in the induction of early growth response protein-1 and thrombospondin-1 by 5-fluorouracil in human cancer carcinoma cells. Int J Oncol 2010;36:1193-200
   PubMed Web of Science ®Google Scholar
• Paasinen-Sohns A, Kaariainen E, Yin M, Chaotic neovascularization induced by aggressive fibrosarcoma cells overexpressing S-adenosylmethionine decarboxylase. Int J Biochem Cell Biol 2011;43:441-54
   Google Scholar
• Nelius T, Filleur S, Yemelyanov A, Androgen receptor targets NFkappaB and TSP1 to suppress prostate tumor growth in vivo. Int J Cancer 2007;121:999-1008
   PubMed Web of Science ®Google Scholar
• Yi J, Chang N, Liu X, Reduced nuclear export of HuR mRNA by HuR is linked to the loss of HuR in replicative senescence. Nucleic Acids Res 2010;38:1547-58
   PubMed Web of Science ®Google Scholar
• Trapp V, Parmakhtiar B, Papazian V, Anti-angiogenic effects of resveratrol mediated by decreased VEGF and increased TSP1 expression in melanoma-endothelial cell co-culture. Angiogenesis 2010;13:305-15
   PubMed Web of Science ®Google Scholar
• Navarro FJ, Mirkin S, Archer DF. Effect of raloxifene, 17beta-estradiol, and progesterone on mRNA for vascular endothelial growth factor isoforms 121 and 165 and thrombospondin-1 in Ishikawa cells. Fertil Steril 2003;79:1409-15
   PubMed Web of Science ®Google Scholar
• Hyder SM, Liang Y, Wu J, Welbern V. Regulation of thrombospondin-1 by natural and synthetic progestins in human breast cancer cells. Endocr Relat Cancer 2009;16:809-17
   PubMed Web of Science ®Google Scholar
• McGray AJ, Gingerich T, Petrik JJ, Lamarre J. Regulation of thrombospondin-1 expression through AU-rich elements in the 3′UTR of the mRNA. Cell Mol Biol Lett 2011;16:55-68
   PubMed Web of Science ®Google Scholar
• Gubin MM, Calaluce R, Davis JW, Overexpression of the RNA binding protein HuR impairs tumor growth in triple negative breast cancer associated with deficient angiogenesis. Cell Cycle 2010;9:3337-46
   PubMed Web of Science ®Google Scholar
• Almog N, Ma L, Raychowdhury R, Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res 2009;69:836-44
   Google Scholar
• van Almen GC, Verhesen W, van Leeuwen RE, MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure. Aging Cell 2011;10:769-79
   PubMed Web of Science ®Google Scholar
• Dews M, Homayouni A, Yu D, Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 2006;38:1060-5
   PubMed Web of Science ®Google Scholar
• Zhao HY, Ooyama A, Yamamoto M, Down regulation of c-Myc and induction of an angiogenesis inhibitor, thrombospondin-1, by 5-FU in human colon cancer KM12C cells. Cancer Lett 2008;270:156-63
   PubMed Web of Science ®Google Scholar
• Gutierrez LS, Suckow M, Lawler J, Thrombospondin 1–a regulator of adenoma growth and carcinoma progression in the AMPMin/+ mouse model. Carcinogenesis 2003;24:199-207
   PubMed Web of Science ®Google Scholar
• Maeda K, Nishiguchi Y, Yashiro M, Expression of vascular endothelial growth factor and thrombospondin-1 in colorectal carcinoma. Int J Mol Med 2000;5:373-8
   PubMed Web of Science ®Google Scholar
• Zhang J, Ito R, Oue N, Expression of thrombospondin-1 is correlated with microvessel density in gastric carcinoma. Virchows Arch 2003;442:563-8
   PubMed Web of Science ®Google Scholar
• Kiyono K, Suzuki HI, Morishita Y, c-Ski overexpression promotes tumor growth and angiogenesis through inhibition of transforming growth factor-beta signaling in diffuse-type gastric carcinoma. Cancer Sci 2009;100:1809-16
   PubMed Web of Science ®Google Scholar
• Yang QW, Liu S, Tian Y, Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma. Cancer Res 2003;63:6299-310
   PubMed Web of Science ®Google Scholar
• Willhauck MJ, Mirancea N, Vosseler S, Reversion of tumor phenotype in surface transplants of skin scc cells by scaffold-induced stroma modulation. Carcinogenesis 2007;28:595-610
   PubMed Web of Science ®Google Scholar
• Giri D, Ittmann M. Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma. Hum Pathol 1999;30:419-24
   PubMed Web of Science ®Google Scholar
• Hsu SC, Volpert OV, Steck PA, Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombospondin-1. Cancer Res 1996;56:5684-91
   PubMed Web of Science ®Google Scholar
• Mascaux C, Martin B, Paesmans M, Expression of thrombospondin in non-small cell lung cancer. Anticancer Res 2002;22:1273-7
   PubMed Web of Science ®Google Scholar
• Hu J, Bianchi F, Ferguson M, Gene expression signature for angiogenic and nonangiogenic non-small-cell lung cancer. Oncogene 2005;24:1212-19
   PubMed Web of Science ®Google Scholar
• Rice A, Quinn CM. Angiogenesis, thrombospondin, and ductal carcinoma in situ of the breast. J Clin Pathol 2002;55:569-74
   PubMed Web of Science ®Google Scholar
• Alvarez AA, Axelrod JR, Whitaker RS, Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients. Gynecol Oncol 2001;82:273-8
   PubMed Web of Science ®Google Scholar
• Wu MP, Tzeng CC, Wu LW, Thrombospondin-1 acts as a fence to inhibit angiogenesis that occurs during cervical carcinogenesis. Cancer J 2004;10:27-32
   PubMed Web of Science ®Google Scholar
• Shariat SF, Youssef RF, Gupta A, Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers. J Urol 2010;183:1744-50
   PubMed Web of Science ®Google Scholar
• Ioachim E, Michael MC, Salmas M, Thrombospondin-1 expression in urothelial carcinoma: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components. BMC Cancer 2006;6:140
   PubMed Web of Science ®Google Scholar
• Zubac DP, Bostad L, Kihl B, The expression of thrombospondin-1 and p53 in clear cell renal cell carcinoma: its relationship to angiogenesis, cell proliferation and cancer specific survival. J Urol 2009;182:2144-9
   PubMed Web of Science ®Google Scholar
• Ordonez JL, Paraoan L, Hiscott P, Differential expression of angioregulatory matricellular proteins in posterior uveal melanoma. Melanoma Res 2005;15:495-502
   PubMed Web of Science ®Google Scholar
• Straume O, Akslen LA. Strong expression of ID1 protein is associated with decreased survival, increased expression of ephrin-A1/EPHA2, and reduced thrombospondin-1 in malignant melanoma. Br J Cancer 2005;93:933-8
   PubMed Web of Science ®Google Scholar
• Velasco P, Lange-Asschenfeldt B. Dermatological aspects of angiogenesis. Br J Dermatol 2002;147:841-52
   PubMed Web of Science ®Google Scholar
• Streit M, Velasco P, Brown LF, Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. Am J Pathol 1999;155:441-52
   PubMed Web of Science ®Google Scholar
• Tang D, Nagano H, Yamamoto H, Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoietin-1/2, thrombospondin-1 and clinicopathological significance. Oncol Rep 2006;15:525-32
   PubMed Web of Science ®Google Scholar
• Albo D, Shinohara T, Tuszynski GP. Up-regulation of matrix metalloproteinase 9 by thrombospondin 1 in gastric cancer. J Surg Res 2002;108:51-60
   PubMed Web of Science ®Google Scholar
• Qian X, Rothman VL, Nicosia RF Tuszynski GP. Expression of thrombospondin-1 in human pancreatic adenocarcinomas: Role in matrix metalloproteinase-9 production. Pathol Oncol Res 2001;7:251-9
   PubMedGoogle Scholar
• Wang TN, Albo D, Tuszynski GP. Fibroblasts promote breast cancer cell invasion by upregulating tumor matrix metalloproteinase-9 production. Surgery 2002;132:220-5
   PubMed Web of Science ®Google Scholar
• John AS, Hu X, Rothman VL, Tuszynski GP. Thrombospondin-1 (TSP-1) up-regulates tissue inhibitor of metalloproteinase-1 (TIMP-1) production in human tumor cells: Exploring the functional significance in tumor cell invasion. Exp Mol Pathol 2009;87:184-8
   PubMed Web of Science ®Google Scholar
• Nathan FE, Hernandez E, Dunton CJ, Plasma thrombospondin levels in patients with gynecologic malignancies. Cancer 1994;73:2853-8
   PubMed Web of Science ®Google Scholar
• Campbell NE, Greenaway J, Henkin J, The thrombospondin-1 mimetic ABT-510 increases the uptake and effectiveness of cisplatin and paclitaxel in a mouse model of epithelial ovarian cancer. Neoplasia 2010;12:275-83
   PubMed Web of Science ®Google Scholar
• Greenaway J, Henkin J, Lawler J, ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer. Mol Cancer Ther 2009;8:64-74
   PubMed Web of Science ®Google Scholar
• Kawataki T, Naganuma H, Sasaki A, Correlation of thrombospondin-1 and transforming growth factor-beta expression with malignancy of glioma. Neuropathology 2000;20:161-9
   PubMed Web of Science ®Google Scholar
• Li Q, Ahuja N, Burger PC, Issa JP. Methylation and silencing of the thrombospondin-1 promoter in human cancer. Oncogene 1999;18:3284-9
   PubMed Web of Science ®Google Scholar
• Zhou L, Picard D, Ra YS, Silencing of thrombospondin-1 is critical for myc-induced metastatic phenotypes in medulloblastoma. Cancer Res 2010;70:8199-210
   PubMed Web of Science ®Google Scholar
• Varani J, McKeever PE, Fligiel SE, Sitrin RG. Plasminogen activator production by human tumor cells: effect on tumor cell-extracellular matrix interactions. Int J Cancer 1987;40:772-7
   PubMed Web of Science ®Google Scholar
• Kawahara N, Ono M, Taguchi K, Enhanced expression of thrombospondin-1 and hypovascularity in human cholangiocarcinoma. Hepatology 1998;28:1512-17
   PubMed Web of Science ®Google Scholar
• Hayashi K, Kurohiji T, Shirouzu K. Localization of thrombospondin in hepatocellular carcinoma. Hepatology 1997;25:569-74
   PubMed Web of Science ®Google Scholar
• Maeno Y, Fujioka H, Hollingdale MR, Ultrastructural localization of CD36 in human hepatic sinusoidal lining cells, hepatocytes, human hepatoma (HepG2-A16) cells, and C32 amelanotic melanoma cells. Exp Parasitol 1994;79:383-90
   PubMed Web of Science ®Google Scholar
• Zak S, Treven J, Nash N Gutierrez LS. Lack of thrombospondin-1 increases angiogenesis in a model of chronic inflammatory bowel disease. Int J Colorectal Dis 2008;23:297-304
   PubMed Web of Science ®Google Scholar
• Punekar S, Zak S, Kalter VG, Thrombospondin 1 and its mimetic peptide ABT-510 decrease angiogenesis and inflammation in a murine model of inflammatory bowel disease. Pathobiology 2008;75:9-21
   PubMed Web of Science ®Google Scholar
• Pfander D, Cramer T, Deuerling D, Expression of thrombospondin-1 and its receptor CD36 in human osteoarthritic cartilage. Ann Rheum Dis 2000;59:448-54
   PubMed Web of Science ®Google Scholar
• Taylor RN, Lebovic DI, Mueller MD. Angiogenic factors in endometriosis. Ann NY Acad Sci 2002;955:89-100; discussion 118, 396–406
   PubMed Web of Science ®Google Scholar
• Tan XJ, Lang JH, Liu DY, Expression of vascular endothelial growth factor and thrombospondin-1 mRNA in patients with endometriosis. Fertil Steril 2002;78:148-53
   PubMed Web of Science ®Google Scholar
• Schellings MW, van Almen GC, Sage EH, Heymans S. Thrombospondins in the heart: Potential functions in cardiac remodeling. J Cell Commun Signal 2009;3:201-13
   PubMed Web of Science ®Google Scholar
• Isenberg JS, Qin Y, Maxhimer JB, Thrombospondin-1 and CD47 regulate blood pressure and cardiac responses to vasoactive stress. Matrix Biol 2009;28:110-19
   PubMed Web of Science ®Google Scholar
• Kang DH, Joly AH, Oh SW, Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1. J Am Soc Nephrol 2001;12:1434-47
   PubMed Web of Science ®Google Scholar
• Hohenstein B, Daniel C, Hausknecht B, Correlation of enhanced thrombospondin-1 expression, TGF-beta signalling and proteinuria in human type-2 diabetic nephropathy. Nephrol Dial Transplant 2008;23:3880-7
   PubMed Web of Science ®Google Scholar
• Hugo C, Kang DH, Johnson RJ. Sustained expression of thrombospondin-1 is associated with the development of glomerular and tubulointerstitial fibrosis in the remnant kidney model. Nephron 2002;90:460-70
   PubMed Web of Science ®Google Scholar
• Garside SA, Henkin J, Morris KD, A thrombospondin-mimetic peptide, ABT-898, suppresses angiogenesis and promotes follicular atresia in pre- and early-antral follicles in vivo. Endocrinology 2010;151:5905-15
   PubMed Web of Science ®Google Scholar
• Garside SA, Harlow CR, Hillier SG, Thrombospondin-1 inhibits angiogenesis and promotes follicular atresia in a novel in vitro angiogenesis assay. Endocrinology 2010;151:1280-9
   PubMed Web of Science ®Google Scholar
• Thomas FH, Wilson H, Silvestri A, Fraser HM. Thrombospondin-1 expression is increased during follicular atresia in the primate ovary. Endocrinology 2008;149:185-92
   PubMed Web of Science ®Google Scholar
• Zamiri P, Masli S, Kitaichi N, Thrombospondin plays a vital role in the immune privilege of the eye. Invest Ophthalmol Vis Sci 2005;46:908-19
   PubMed Web of Science ®Google Scholar
• Masli S, Turpie B, Streilein JW. Thrombospondin orchestrates the tolerance-promoting properties of TGFbeta-treated antigen-presenting cells. Int Immunol 2006;18:689-99
   PubMed Web of Science ®Google Scholar
• Turpie B, Yoshimura T, Gulati A, Sjogren's syndrome-like ocular surface disease in thrombospondin-1 deficient mice. Am J Pathol 2009;175:1136-47
   PubMed Web of Science ®Google Scholar
• He S, Incardona F, Jin M, Thrombospondin-1 expression in RPE and choroidal neovascular membranes. Yan Ke Xue Bao 2006;22:265-74
   PubMedGoogle Scholar
• Uno K, Bhutto IA, McLeod DS, Impaired expression of thrombospondin-1 in eyes with age related macular degeneration. Br J Ophthalmol 2006;90:48-54
   PubMed Web of Science ®Google Scholar
• Wang S, Gottlieb JL, Sorenson CM, Sheibani N. Modulation of thrombospondin 1 and pigment epithelium-derived factor levels in vitreous fluid of patients with diabetes. Arch Ophthalmol 2009;127:507-13
   PubMed Web of Science ®Google Scholar
• Scheef EA, Sorenson CM, Sheibani N. Attenuation of proliferation and migration of retinal pericytes in the absence of thrombospondin-1. Am J Physiol Cell Physiol 2009;296:C724-34
   PubMed Web of Science ®Google Scholar
• Mousa SA, Lorelli W, Campochiaro PA. Role of hypoxia and extracellular matrix-integrin binding in the modulation of angiogenic growth factors secretion by retinal pigmented epithelial cells. J Cell Biochem 1999;74:135-43
   PubMed Web of Science ®Google Scholar
• Iruela-Arispe ML, Luque A, Lee N. Thrombospondin modules and angiogenesis. Int J Biochem Cell Biol 2004;36:1070-8
   PubMed Web of Science ®Google Scholar
• Johnson ES, Seely JH, White WF, DeSombre ER. Endocrine-dependent rat mammary tumor regression: use of a gonadotropin releasing hormone analog. Science 1976;194:329-30
   PubMed Web of Science ®Google Scholar
• Haviv F, Bradley MF, Kalvin DM, Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities. J Med Chem 2005;48:2838-46
   PubMed Web of Science ®Google Scholar
• Reiher FK, Volpert OV, Jimenez B, Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics. Int J Cancer 2002;98:682-9
   PubMed Web of Science ®Google Scholar
• Rusk A, McKeegan E, Haviv F, Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers. Clin Cancer Res 2006;12:7444-55
   PubMed Web of Science ®Google Scholar
• Shaked Y, Bertolini F, Man S, Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 2005;7:101-11
   PubMed Web of Science ®Google Scholar
• Quesada AJ, Nelius T, Yap R, In vivo upregulation of CD95 and CD95L causes synergistic inhibition of angiogenesis by TSP1 peptide and metronomic doxorubicin treatment. Cell Death Differ 2005;12:649-58
   PubMed Web of Science ®Google Scholar
• Yap R, Veliceasa D, Emmenegger U, Metronomic low-dose chemotherapy boosts cd95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy. Clin Cancer Res 2005;11:6678-85
   PubMed Web of Science ®Google Scholar
• Isenberg JS, Yu C, Roberts DD. Differential effects of ABT-510 and a CD36-binding peptide derived from the type 1 repeats of thrombospondin-1 on fatty acid uptake, nitric oxide signaling, and caspase activation in vascular cells. Biochem Pharmacol 2008;75:875-82
   PubMed Web of Science ®Google Scholar
• Rath GM, Schneider C, Dedieu S, Thrombospondin-1 C-terminal-derived peptide protects thyroid cells from ceramide-induced apoptosis through the adenylyl cyclase pathway. Int J Biochem Cell Biol 2006;38:2219-28
   PubMed Web of Science ®Google Scholar
• Anderson JC, Grammer JR, Wang W, ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma growth in vivo by inhibiting angiogenesis. Cancer Biol Ther 2007;6:454-62
   PubMed Web of Science ®Google Scholar
• Nabors LB, Fiveash JB, Markert JM, A Phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma. Arch Neurol 2010;67:313-19
   PubMedGoogle Scholar
• Stupp R, Mason WP, van den Bent MJ, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96
   PubMed Web of Science ®Google Scholar
• Hoekstra R, de Vos FY, Eskens FA, Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer. J Clin Oncol 2005;23:5188-97
   PubMed Web of Science ®Google Scholar
• Gietema JA, Hoekstra R, de Vos FY, A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors. Ann Oncol 2006;17:1320-7
   PubMed Web of Science ®Google Scholar
• Gordon MS, Mendelson D, Carr R, A Phase 1 trial of 2 dose schedules of ABT-510, an antiangiogenic, thrombospondin-1-mimetic peptide, in patients with advanced cancer. Cancer 2008;113:3420-9
   PubMed Web of Science ®Google Scholar
• Ebbinghaus S, Hussain M, Tannir N, Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma. Clin Cancer Res 2007;15:6689-95
   Web of Science ®Google Scholar
• Markovic SN, Suman VJ, Rao RA, A Phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. Am J Clin Oncol 2007;30:303-9
   PubMed Web of Science ®Google Scholar
• Baker LH, Rowinsky EK, Mendelson D, Randomized, Phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma. J Clin Oncol 2008;26:5583-8
   PubMed Web of Science ®Google Scholar
• Yang Q, Tian Y, Liu S, Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma. Cancer Res 2007;67:1716-24
   PubMed Web of Science ®Google Scholar
• Fukumura D, Jain RK. Tumor microvasculature and microenvironment: Targets for anti-angiogenesis and normalization. Microvasc Res 2007;74:72-84
   PubMed Web of Science ®Google Scholar
• Hasina R, Martin LE, Kasza K, Abt-510 is an effective chemopreventive agent in the mouse 4-nitroquinoline 1-oxide model of oral carcinogenesis. Cancer Prev Res (Phila) 2009;2:385-93
   PubMed Web of Science ®Google Scholar
• Thaunat O, Louedec L, Graff-Dubois S, Antiangiogenic treatment prevents adventitial constrictive remodeling in graft arteriosclerosis. Transplantation 2008;85:281-9
   PubMed Web of Science ®Google Scholar
• Campbell N, Greenaway J, Henkin J Petrik J. ABT-898 induces tumor regression and prolongs survival in a mouse model of epithelial ovarian cancer. Mol Cancer Ther 2011;10:1876-85
   PubMed Web of Science ®Google Scholar